Normal view MARC view ISBD view

Palliative chemotherapy in carcinoma nasopharynx

In South Asian Journal of Cancer
By: Patil VM.
Contributor(s): Joshi A | Noronha V | Talreja V | Simha V | Dhumal S | Bandekar B | Chandrasekharan A | Kumar Prabhash [Corresponding Author].
Material type: materialTypeLabelArticlePublisher: 2019Description: .Subject(s): Chemotherapy | Nasopharynx | Palliative | Quality‑adjusted Time without Symptoms or Toxicity | Systemic In: South Asian Journal of Cancer Vol. 08, no. 03, p. 173-177.Summary: Introduction: Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma nasopharynx and studied their outcomes. Methods: Patients who underwent first‑line palliative systemic chemotherapy between January 2014 and April 2017 for carcinoma nasopharynx at the department of medical oncology at authors’ institute were selected for this analysis. Toxicities, responses, progression‑free survival (PFS), and overall survival (OS) were analyzed. In addition, a Quality‑Adjusted Time without Symptoms or Toxicity analysis with threshold utility analysis was performed. Results: Fifty‑one patients were included in this analysis. The indication of palliative chemotherapy was locoregionally recurrent disease in 25 (49.0%) patients and metastatic disease in 26 (51.0%) patients. The overall response rate was 62.0% (n = 33). The median PFS was 225 days (95% confidence interval [CI]: 164–274 days) and median OS was 513 days (95% CI: 286–931 days). The restricted mean TOX state duration was 2.6 days (95% CI: 0.3–4.9), restricted mean TWiST duration was 219.2 days(95% CI: 184.0–254.4), and restricted mean REL duration was 74.3 days(95% CI: 38.1–110.4). Conclusion: Systemic cytotoxic therapy in nasopharyngeal cancers is associated with high response rates and clinically meaningful PFS; with low duration of time spent in adverse events
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19591

Address for Corresponding Author: kumarprabhashtmh@gmail.com

Introduction: Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma
nasopharynx and studied their outcomes. Methods: Patients who underwent first‑line palliative systemic chemotherapy between January 2014 and April 2017
for carcinoma nasopharynx at the department of medical oncology at authors’ institute were selected for this analysis. Toxicities, responses, progression‑free
survival (PFS), and overall survival (OS) were analyzed. In addition, a Quality‑Adjusted Time without Symptoms or Toxicity analysis with threshold utility
analysis was performed. Results: Fifty‑one patients were included in this analysis. The indication of palliative chemotherapy was locoregionally recurrent
disease in 25 (49.0%) patients and metastatic disease in 26 (51.0%) patients. The overall response rate was 62.0% (n = 33). The median PFS was 225 days
(95% confidence interval [CI]: 164–274 days) and median OS was 513 days (95% CI: 286–931 days). The restricted mean TOX state duration was 2.6 days
(95% CI: 0.3–4.9), restricted mean TWiST duration was 219.2 days(95% CI: 184.0–254.4), and restricted mean REL duration was 74.3 days(95% CI: 38.1–110.4).
Conclusion: Systemic cytotoxic therapy in nasopharyngeal cancers is associated with high response rates and clinically meaningful PFS; with low duration
of time spent in adverse events

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha